blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3193911

EP3193911 - IMPROVED FACTOR VIII PREPARATIONS FOR USE IN TREATING HEMOPHILIA A [Right-click to bookmark this link]
Former [2017/30]IMPROVED FACTOR VIII PREPARATIONS SUITABLE FOR THERAPEUTIC USE AND PROCESSES TO OBTAIN THESE
[2023/13]
StatusNo opposition filed within time limit
Status updated on  12.07.2024
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  04.08.2023
FormerGrant of patent is intended
Status updated on  04.04.2023
FormerExamination is in progress
Status updated on  20.07.2018
FormerRequest for examination was made
Status updated on  23.06.2017
FormerThe international publication has been made
Status updated on  25.02.2017
Most recent event   Tooltip02.08.2024Lapse of the patent in a contracting state
New state(s): SI		published on 04.09.2024  [2024/36]
Applicant(s)For all designated states
CSL Behring GmbH
Emil-von-Behring-Strasse 76
35041 Marburg / DE
[2023/36]
Former [2017/30]For all designated states
CSL Behring GmbH
Emil-von-Behring-Strasse 76
35041 Marburg / DE
Inventor(s)01 / SCHMIDBAUER, Stefan
Am Hofacker 11
35094 Lahntal / DE
02 / METZNER, Hubert
Im Boden 6
35041 Marburg / DE
03 / ROBBEL, Lars
Elbinger Strasse 12
35083 Wetter / DE
 [2017/30]
Representative(s)CSL Global IP
C/o CSL Behring GmbH
Global Intellectual Property
Emil-von-Behring-Straße 76
35041 Marburg / DE
[2023/36]
Former [2017/30]Hauser, Hans-Peter, et al
CSL Behring GmbH Patents & Licenses Emil-von-Behring-Strasse 76
35041 Marburg / DE
Application number, filing date15741222.224.07.2015
[2017/30]
WO2015EP67014
Priority number, dateEP2014017856325.07.2014         Original published format: EP 14178563
[2017/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016012595
Date:28.01.2016
Language:EN
[2016/04]
Type: A1 Application with search report 
No.:EP3193911
Date:26.07.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 28.01.2016 takes the place of the publication of the European patent application.
[2017/30]
Type: B1 Patent specification 
No.:EP3193911
Date:06.09.2023
Language:EN
[2023/36]
Search report(s)International search report - published on:EP28.01.2016
ClassificationIPC:A61K38/37, A61P7/04
[2017/30]
CPC:
A61K38/37 (EP,US); A61P7/04 (EP); G01N33/68 (US);
G01N2333/755 (US); G01N33/15 (US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/30]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:VERBESSERTE FAKTOR-VIII-PRÄPARATE ZUR VERWENDUNG IN DER BEHANDLUNG VON HÄMOPHILIE A[2023/13]
English:IMPROVED FACTOR VIII PREPARATIONS FOR USE IN TREATING HEMOPHILIA A[2023/13]
French:PRÉPARATIONS DE FACTEUR VIII AMÉLIORÉES POUR L'UTILISATION DANS LE TRAITEMENT DE L'HÉMOPHILIE A[2023/13]
Former [2017/30]VERBESSERTE FAKTOR-VIII-PRÄPARATIONEN FÜR THERAPEUTISCHE VERWENDUNG UND VERFAHREN ZUR ERHALTUNG DERSELBEN
Former [2017/30]IMPROVED FACTOR VIII PREPARATIONS SUITABLE FOR THERAPEUTIC USE AND PROCESSES TO OBTAIN THESE
Former [2017/30]PRÉPARATIONS AMÉLIORÉES DE FACTEUR VIII APPROPRIÉS POUR UNE UTILISATION THÉRAPEUTIQUE ET LEURS PROCÉDÉS D'OBTENTION
Entry into regional phase27.02.2017National basic fee paid 
27.02.2017Designation fee(s) paid 
27.02.2017Examination fee paid 
Examination procedure24.02.2017Date on which the examining division has become responsible
27.02.2017Examination requested  [2017/30]
20.09.2017Amendment by applicant (claims and/or description)
23.07.2018Despatch of a communication from the examining division (Time limit: M04)
30.11.2018Reply to a communication from the examining division
10.12.2019Despatch of a communication from the examining division (Time limit: M04)
24.03.2020Reply to a communication from the examining division
12.10.2020Despatch of a communication from the examining division (Time limit: M06)
17.03.2021Reply to a communication from the examining division
29.06.2021Despatch of a communication from the examining division (Time limit: M04)
27.10.2021Reply to a communication from the examining division
02.05.2022Despatch of a communication from the examining division (Time limit: M04)
06.09.2022Reply to a communication from the examining division
05.04.2023Communication of intention to grant the patent
31.07.2023Fee for grant paid
31.07.2023Fee for publishing/printing paid
31.07.2023Receipt of the translation of the claim(s)
Opposition(s)07.06.2024No opposition filed within time limit [2024/33]
Fees paidRenewal fee
31.07.2017Renewal fee patent year 03
31.07.2018Renewal fee patent year 04
31.07.2019Renewal fee patent year 05
31.07.2020Renewal fee patent year 06
02.08.2021Renewal fee patent year 07
01.08.2022Renewal fee patent year 08
31.07.2023Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ06.09.2023
EE06.09.2023
FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
RO06.09.2023
RS06.09.2023
SI06.09.2023
SK06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
[2024/36]
Former [2024/23]CZ06.09.2023
EE06.09.2023
FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
RO06.09.2023
RS06.09.2023
SK06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
Former [2024/20]FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
RS06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
Former [2024/11]FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
RS06.09.2023
NO06.12.2023
GR07.12.2023
Former [2024/09]FI06.09.2023
LT06.09.2023
NO06.12.2023
GR07.12.2023
Former [2024/08]LT06.09.2023
NO06.12.2023
GR07.12.2023
Cited inInternational search[XY]WO0023116  (AVIGEN INC [US], et al) [X] 1-3,5-12 * abstract * * page 1, line 9 * * page 32, lines 13-20 * * example 10 * [Y] 1-15;
 [XY]WO2013057219  (CSL BEHRING GMBH [DE], et al) [X] 1,3-8,10-12 * abstract * * page 2, line 6 * * page 3, lines 12-14 * * examples 1,3,5 * [Y] 1-15;
 [XY]  - WAKABAYASHI HIRONAO ET AL, "Ca2+ binding to both the heavy and light chains of factor VIII is required for cofactor activity", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (20020702), vol. 41, no. 26, doi:10.1021/BI025589O, ISSN 0006-2960, pages 8485 - 8492, XP002410844 [X] 1,3,5,6,8,10,13,14 * the whole document * [Y] 1-15

DOI:   http://dx.doi.org/10.1021/bi025589o
ExaminationWO9109122
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.